Search results
The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein.
May 9, 2024 · Beximco Pharmaceuticals is forecast to grow earnings and revenue by 15.6% and 12.8% per annum respectively. EPS is expected to grow by 18.3% per annum. Return on equity is forecast to be 14.8% in 3 years.
BLOOMBERG: BXPHAR:BD. damentalsBeximco Pharmaceuticals Limited (BXPHARMA) commenced its manufacturing operatio. in 1980. The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products including life-saving intravenous fluids and Active Pharmaceuticals Ingredients (APIs) for both national and internation.
5 days ago · 1976. n/a. n/a. www.beximcopharma.com. Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine ...
- ৳0.45
- 0.60
- ৳0.19
- ৳0.24
View the real-time Beximco Pharmaceuticals Ltd (BXPH) stock price. Assess historical data, charts, technical analysis and contribute in the forum.
Aug 21, 2024 · Investment Themes Homepage; Private Equity ... 2022 2023 2024 ... Cash Flow Forecast: Beximco Pharmaceuticals Limited. Fiscal Period: June 2019
May 9, 2024 · Future criteria checks 2/6. Beximco Pharmaceuticals is forecast to grow earnings and revenue by 15.6% and 12.8% per annum respectively. EPS is expected to grow by 18.3% per annum. Return on equity is forecast to be 14.8% in 3 years.
